Indeed, by identifying HMGB1 as a potential target of salicylates in our experimental MM system, we provide a proof-of-concept of a novel therapeutic mechanism that is responsible for aspirin's anticancer effects. The gene discussed is HMGB1; the disease is Miyoshi myopathy.